Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
8 Results Found
AHA Letter to CMS on Medicare Transaction Facilitator and Drug Negotiation Program
AHA shares feedback in response to the Centers for Medicare & Medicaid Services’ information collection request (ICR) regarding the Medicare Transaction Facilitator (MTF) and the Medicare drug negotiation program.
AHA Urges HRSA to Take Immediate Enforcement Action to Block J&J’s Illegal Imposition of 340B Rebate Model
AHA letter regarding the Health Resources and Services Administration’s response to Johnson & Johnson’s (J&J) most recent attempt to undermine the 340B Drug Pricing Program.
AHA Comments on 340B Drug Pricing Program, IRF Payments, Physician Fee Schedule and Telehealth
AHA comments on MedPAC topics to be considered in the new cycle: the 340B Drug Pricing Program, inpatient rehabilitation facility (IRF) payments, the physician fee schedule (PFS) and telehealth.
AHA Comments Opposing the 340B ACCESS Act (H.R. 8574)
The American Hospital Association (AHA) expresses their opposition to H.R. 8574, the 340B Affording Care for Communities and Ensuring a Strong Safety-net (340B ACCESS) Act.
AHA Submits Comments on CMS Guidance For Medicare Drug Price Negotiation Program
AHA shares feedback on the Centers for Medicare & Medicaid Services’ draft guidance on the Medicare drug price negotiation program.
AHA Letter to House Energy and Commerce Committees on Value of 340B Program
AHA expresses strong support for the 340B program and urges Congress to protect this critical program as it has done for more than three decades.
AHA Responds to Senate RFI on the SUSTAIN 340B Act Draft
AHA welcomes the opportunity to provide feedback on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of (SUSTAIN) 340B Act bipartisan discussion draft and accompanying request for information on the critically important 340B Drug Pricing Program.
Deadline Extended Until Oct. 29 for Your Representatives to Sign ‘Dear Colleague’ Letter Urging HHS to Take Action
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary Alex Azar expressing concern about recent efforts by Kalderos to transition the 340B Drug Pricing Program from one of up-front discounts to post-sale rebates.